⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JANX News
Janux Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
JANX
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
businesswire.com
JANX
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment
businesswire.com
JANX
BMY
Form 8-K
sec.gov
JANX
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
businesswire.com
JANX
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
businesswire.com
JANX
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
businesswire.com
JANX
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer
businesswire.com
JANX
GILD
AMGN
Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study
businesswire.com
JANX
Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC
businesswire.com
JANX